论文部分内容阅读
目的 检测乳腺癌骨髓微转移 ,探讨其与乳腺癌临床病理学因素的关系。方法 采用RT -PCR法 (一步法 )检测骨髓中CK19mRNA表达。结果 10 2例乳腺癌患者骨髓CK19mR NA表达阳性率 5 6.9%。骨髓CK19mRNA表达率随乳腺癌肿块增大而增高 ;随临床分期增加而增高 ;随组织学分级增加而增高。但与腋淋巴结转移与否无关 ,亦与乳腺癌患者年龄、月经状况及病理类型无关。结论 乳腺癌骨髓微转移与某些临床病理学因素有关。癌细胞播散无固定模式 ,早期乳腺癌亦可发生远处转移。骨髓微转移应作为常规检测方法 ,以更早、更准确地预测全身转移情况 ,进行个体化治疗。
Objective To detect the bone marrow micrometastases in breast cancer and to explore its relationship with the clinicopathological factors of breast cancer. Methods The expression of CK19mRNA in bone marrow was detected by RT-PCR (one-step method). Results The positive rate of CK19mRNA expression in bone marrow of 10 2 breast cancer patients was 59.9%. The expression of CK19mRNA in bone marrow increased with the increase of breast cancer mass, increased with the increase of clinical stage, and increased with the increase of histological grade. But with axillary lymph node metastasis or not, but also with breast cancer patients age, menstrual status and pathological type has nothing to do. Conclusion Bone marrow micrometastases in breast cancer are associated with some clinicopathological factors. Cancer cells disseminated without a fixed pattern, early breast cancer can also occur distant metastasis. Bone marrow micrometastases should be used as routine tests to predict systemic metastases earlier and more accurately for individualized treatment.